Advancing influenza virus treatment: <i>in vitro</i> and <i>ex vivo</i> studies of PI3K inhibitor-loaded lipid nanoparticles.

ABSTRACT: Influenza A viruses (IAVs) remain a significant global health concern, causing seasonal outbreaks and pandemics with substantial morbidity and mortality, particularly among vulnerable groups. Annual vaccination serves as the primary preventative measure, but its limited effectiveness against emerging subtypes and insufficient coverage underscore the urgent need for novel antiviral strategies. Resistance to Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved direct antivirals further emphasizes this necessity. Host-directed therapeutic strategies, such as those targeting phosphatidylinositol 3-kinases (PI3Ks), which are utilized by IAVs during replication, offer promising alternatives to reduce infection severity. In parallel, advances in nanotechnology have fac

SUBMITTER: Schroeder J 

PROVIDER: S-EPMC12704091 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature